Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL288 Target Snapshot

3',5'-cyclic-AMP phosphodiesterase 4D · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
4,535Compounds
399Assays
11Approved Drugs
3,788.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

3',5'-cyclic-AMP phosphodiesterase 4D shows late clinical disease relevance led by fragile X syndrome. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q08499. Start with fragile X syndrome, then reuse UniProt Q08499 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with fragile X syndrome, then reuse UniProt Q08499 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
fragile X syndrome

3',5'-cyclic-AMP phosphodiesterase 4D shows late clinical disease relevance led by fragile X syndrome. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with fragile X syndrome because it currently carries late clinical support. Linked drugs include ZATOLMILAST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 3',5'-cyclic-AMP phosphodiesterase 4D as ChEMBL target CHEMBL288, mapped to UniProt Q08499. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
3',5'-cyclic-AMP phosphodiesterase 4D
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL288
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q08499
3',5'-cyclic-AMP phosphodiesterase 4D
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 3',5'-cyclic-AMP phosphodiesterase 4D is the right protein anchor across sources, using UniProt Q08499 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why fragile X syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name3',5'-cyclic-AMP phosphodiesterase 4D
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ08499
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label3',5'-cyclic-AMP phosphodiesterase 4D
UniProt AccessionQ08499
Component TypeProtein
Sequence Length809 aa

3',5'-cyclic-AMP phosphodiesterase 4D

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 3',5'-cyclic-AMP phosphodiesterase 4D, mapped to UniProt Q08499. Sequence length is 809 aa.

Mapped IDQ08499
Review name3',5'-cyclic-AMP phosphodiesterase 4D
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

3',5'-cyclic-AMP phosphodiesterase 4D shows late clinical disease relevance led by fragile X syndrome. 2 more disease programs remain visible in the same review block.

Late clinical Phase III
fragile X syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugZATOLMILAST
Clinical signal Phase II
Alzheimer disease
1 linked drug · 1 direct · 1 efficacy
Linked drugZATOLMILAST
Clinical signal Phase I
cognitive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugZATOLMILAST
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with fragile X syndrome because it currently carries late clinical support. Linked drugs include ZATOLMILAST. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasefragile X syndrome
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

11
Approved
4
Phase III
20
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC503,615.0
KI155.0
EC509.0
KD9.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL42126 10.7 IC50 0.02 Clinical
CHEMBL3288029 10.7 IC50 0.01995 Preclinical
CHEMBL3288030 10.7 IC50 0.01995 Preclinical
CHEMBL4566742 10.21 Ki 0.06166 Preclinical
CHEMBL1830646 10.0 IC50 0.1 Preclinical
CHEMBL377709 10.0 IC50 0.1 Preclinical
CHEMBL380321 10.0 IC50 0.1 Preclinical
CHEMBL382168 10.0 IC50 0.1 Preclinical
CHEMBL206968 10.0 IC50 0.1 Preclinical
CHEMBL4435111 9.92 Ki 0.1202 Preclinical
Distribution

pChEMBL Value Distribution

275
5.0
271
5.5
294
6.0
238
6.5
204
7.0
203
7.5
117
8.0
76
8.5
78
9.0
22
9.5
pChEMBL
Approved Drugs

Approved Drugs

CRISABOROLE
CHEMBL484785
Approved 2016
Properties Compare Identifier
APREMILAST
CHEMBL514800
Approved 2014
Properties Compare Identifier
ROFLUMILAST
CHEMBL193240
Approved 2010
Properties Compare Identifier
IBUDILAST
CHEMBL19449
Approved 1989
Properties Compare Identifier
Assay Landscape

Assay Landscape

399
Total Assays
1,597
Tested Compounds
3
Assay Types
Binding — 366 assays, 1,597 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 264 931 6.7
assay format 54 451 6.2
cell-based format 46 196 5.9
cell-free format 1 1 7.4
tissue-based format 1 18 4.4
ADME — 20 assays, 88 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 10 16 6.0
cell-based format 7 33 5.4
assay format 3 39 8.0
Functional — 13 assays, 10 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 10 6 7.0
tissue-based format 2 2 8.0
cell-based format 1 2 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine